SBIR Phase I: RAPID Integrated and automated genomics platform for hospitals responding to COVID-19

SBIR 第一阶段：用于医院应对 COVID-19 的 RAPID 集成自动化基因组学平台

• 批准号: 2027424
• 负责人: Susanna Lamers
• 金额: $ 25.6万
• 依托单位: Bioinfoexperts, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2021-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2027424&HistoricalAwards=false
• 关键词: SBIR; Phase; RAPID; Integrated; automated

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project will be a user-friendly and scalable infection control surveillance software platform using advanced biotech and data analytics for monitoring the COVID-19 pandemic. The COVID-19 pandemic highlights the need for rapid testing, analysis, and tracking. The innovation provides access to next-generation sequence technologies to healthcare facilities, as well as a centralized system to integrate and share hospital-level data with microbial information to be shared on any geographic scale. The platform automates the analysis of bacterial and viral data, delivering simplified and clinically relevant results via interactive web interfaces. The proposed technology offers important data to clinicians and other experts. The intellectual merit of this SBIR Phase I project is to generate the largest collection of SARS-CoV-2 whole genomes with matched respiratory microbiomes for clinicians to rapidly test medical hypotheses for diagnostic and prescriptive use. Our project has three major objectives: 1) incorporate an automated analytical pipeline to process whole genomes of infecting strains of SARS-CoV-2; 2) integrate viral genomes with patient microbiomes and clinical records, and; 3) deliver clear, easy-to-interpret results via an interactive web interface. The infection control cloud-based software platform solution enables “precision epidemiology” integrating pathogen genomics with clinical and patient demographics to improve patient outcomes and enhance the capability of the health system for infection control and surveillance.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业创新研究第一阶段项目的更广泛的影响/商业潜力将是一个用户友好和可扩展的感染控制监测软件平台，使用先进的生物技术和数据分析来监测新冠肺炎疫情。新冠肺炎大流行凸显了快速检测、分析和跟踪的必要性。这项创新提供了对医疗设施的下一代序列技术的访问，以及一个集中式系统，以集成和共享医院级数据和微生物信息，以便在任何地理范围内共享。该平台自动分析细菌和病毒数据，通过交互式网络界面提供简化的和临床相关的结果。这项拟议的技术为临床医生和其他专家提供了重要数据。SBIR第一阶段项目的智力优势是为临床医生生成最大的SARS-CoV-2全基因组和匹配的呼吸道微生物群，以快速测试用于诊断和处方使用的医学假说。我们的项目有三个主要目标：1)采用自动化分析管道来处理感染SARS-CoV-2毒株的全基因组；2)将病毒基因组与患者微生物群和临床记录相结合；3)通过交互式网络界面提供清晰、易于解释的结果。基于云的感染控制软件平台解决方案使“精确流行病学”能够将病原体基因组学与临床和患者人口统计学相结合，以改善患者结局并增强卫生系统的感染控制和监测能力。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。